The Berenberg Bank Analysts Give Sanofi SA (SAN) a €97.00 Price Target

The Berenberg Bank Analysts Give Sanofi SA (SAN) a €97.00 Price Target

Other equities analysts have also issued reports about the company. JPMorgan Chase & Co. set a €87.00 ($97.75) target price on Sanofi SA and gave the stock a “neutral” rating in a research report on Tuesday, April 11th. Morgan Stanley set a €91.00 ($102.25) target price on Sanofi SA and gave the stock a “buy” rating in a research report on Wednesday, March 29th. Deutsche Bank AG set a €96.00 ($107.87) target price on Sanofi SA and gave the stock a “buy” rating in a research report on Tuesday, April 11th. HSBC Holdings plc set a €77.00 ($86.52) target price on Sanofi SA and gave the stock a “sell” rating in a research report on Friday, April 7th. Finally, Societe Generale set a €100.00 ($112.36) price target on Sanofi SA and gave the company a “buy” rating in a research report on Thursday, March 23rd. Two investment analysts have rated the stock with a sell rating, eleven have given a hold rating and four have issued a buy rating to the company. The stock has an average rating of “Hold” and an average price target of €86.44 ($97.12).

Sanofi SA (EPA:SAN) has been assigned a €97.00 ($108.99) price target by stock analysts at Berenberg Bank in a note issued to investors on Thursday, May 11th. The brokerage currently has a “neutral” rating on the stock.

Sanofi SA (EPA SAN) traded up 1.13% during trading on Thursday, hitting €88.87. 2,057,016 shares of the company traded hands. The stock has a 50-day moving average price of €25.48 and a 200-day moving average price of €25.74. The firm has a market capitalization of €112.22 billion and a P/E ratio of 12.29. Sanofi SA has a 12-month low of €62.50 and a 12-month high of €92.97.

Sanofi SA Company Profile

Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.

Related posts

Leave a Comment